1. Home
  2. CMII vs TENX Comparison

CMII vs TENX Comparison

Compare CMII & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CMII

Columbus Circle Capital Corp II Class A Ordinary Shares

N/A

Current Price

$10.02

Market Cap

318.0M

Sector

N/A

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.71

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMII
TENX
Founded
2025
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
318.0M
317.8M
IPO Year
2026
2001

Fundamental Metrics

Financial Performance
Metric
CMII
TENX
Price
$10.02
$1.71
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
67.1K
6.7M
Earning Date
N/A
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.76
$1.31
52 Week High
$10.22
$19.40

Technical Indicators

Market Signals
Indicator
CMII
TENX
Relative Strength Index (RSI) 45.38 18.34
Support Level N/A $1.31
Resistance Level $10.19 $16.39
Average True Range (ATR) 0.01 0.81
MACD 0.00 -1.36
Stochastic Oscillator 50.00 3.48

Price Performance

Historical Comparison
CMII
TENX

About CMII Columbus Circle Capital Corp II Class A Ordinary Shares

Columbus Circle Capital Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: